Venetoclax Combined with Intensive Therapy for Acute Myeloid Leukemia Patients with Lower Early Peripheral Blast Clearance Rate After Standard Induction Therapy

Prior treatment

• Participants who have received prior treatment for AML with chemotherapy, hypomethylating agents, or venetoclax
• Participants with a prior history of MDS, MPN, or MDS/MPN
• Participants with other concurrent malignant tumors on treatment, except for:
  • Malignancy treated with curative intent and with no known active disease present for ≧3 years
  • Adequately treated non-melanoma skin cancer or lentigo maligna without current evidence of disease
  • Adequately treated carcinoma in situ without current evidence of disease
  • Localized prostate cancer with a Gleason score of 6 or less
• Active heart disease is defined as any one of the following:
  • Uncontrolled or symptomatic angina pectoris
  • A myocardial infarction six months before enrolled
  • Arrhythmia needs medication or with severe clinical symptoms
  • Uncontrolled or symptomatic congestive heart failure (New York Hear Association \[NYHA\] classification\> grade 2)

Other illness

• Participants with an active, uncontrolled, systemic fungal, bacterial, or viral infection without improvement despite appropriate antibiotics, antiviral therapy, and/or other treatment
• Participants with an active viral infection caused by HIV, hepatitis B, or hepatitis C virus that cannot be controlled by treatment
• Participants with epilepsy which needs drug treatment, dementia, or other abnormal mental states that prevent understanding or following the protocol
• Conditions that restrict the intake or absorption of orally administered drugs

Lab values

• Participants who are ineligible for intensive induction chemotherapy:
  • ≧71 years old OR
  • ≧18 to 70 years old and fulfill at least one criterion associated with lack of fitness for intensive induction chemotherapy:
  • ECOG PS of 2-3
  • Cardiac history of CHF requiring treatment or Ejection Fraction ≦50% or chronic stable angina
  • Diffusing capacity of the lungs for carbon monoxide (DLCO)≦65% or the forced expiratory volume in one second (FEVI) ≦65%

Other

• AML with BCR-ABL1 or myeloid blast crisis of CML
• Pregnant or lactating women
• Participants with evidence of central nervous system leukemia before the study treatment

• Newly diagnosed AML, except for the APL subtype, according to the 2022 World Health Organization classification (WHO 2022 criteria)
• Age ≥18 years and ≤70 years
• Eligible for intensive chemotherapy
• No prior chemotherapy for AML except hydroxyurea for up to 14 days during the diagnostic screening phase for the control of peripheral leukemic blasts in patients with leukocytosis (e.g., white blood cell \[WBC\] counts\>25x10\^9/L)
• Eastern Cooperative Oncology Group (ECOG) performance status≤2
• Adequate renal function is defined as:
  • Serum creatinine≤2.0×upper limit of normal (ULN)
  • Creatinine clearance (CrCl)\>30 mL/min calculated by the Cockcroft-Gault equation.
• Adequate hepatic and heart function is defined as:
  • Serum total bilirubin≤1.5×ULN unless considered due to Gilbert's disease, or leukemic involvement
  • Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP)≤2.5×ULN, unless considered due to leukemic involvement
  • Myocardial enzyme\<2.0×ULN
  • Left ventricular ejection fraction is within the normal range by measure of echocardiogram (ECHO)
• Signed a written informed consent form (ICF)
• Female participants who are of non-reproductive potential (i.e., post-menopausal by history of no menses for ≥1 year; OR history of hysterectomy; OR history of bilateral tubal ligation; OR history of bilateral oophorectomy). Female participants of childbearing potential must have a negative serum pregnancy test upon study entry